Monday, September 19, 2022

Register NOW for Free Symposium with lunch at the Four Seasons!


15th Annual Learning for Living Symposium

November 19, 2022

Four Seasons Hotel Boston


Speakers will include:

Ursula Matulonis, MD, Leslie Garrett, MD, Katharine Esselen, MD, 

Sharon Bober, Ph.D and author Donna Wiegle will share her "Teal on Wheels" Adventure!



 This is a FREE event for ovarian cancer patients, their caregivers, support community and those in the medical field working in gynecologic oncology.

 Continental breakfast starts at 8am.  Speaker presentations will run from 8:30 to 12:30 with breaks and the opportunity to visit our sponsors display tables.

A delicious plated lunch will be served from 12:30 to 2pm

 Valet parking is available at the hotel at no cost with thanks to our sponsors support!

Friday, September 16, 2022

Upcoming Dana-Farber Virtual Symposium

Monday, September 26th  
 Dana-Farber Gynecologic Oncology
Virtual Symposium Series
A series of free online educational programs for patients and their loved ones
Monday, Sept. 26 | 5:30-6:30 p.m. ET
Join Drs. Matulonis, Campos, and Porter for a round table discussion about the latest research and treatments in gynecologic cancers. Please feel free to submit your questions in advance on the Zoom registration page.

Friday, August 26, 2022

Niraprib Maintenance Prolongs PFS in Newly Diagnosed Advanced Ovarian Cancer After Response to Chemotherapy

This is an edited version of an article written by Chris Ryan and published in OncLive July 26, 2022

Maintenance therapy with niraparib (Zejula) significantly improved progression-free survival (PFS) compared with placebo in Chinese patients with newly diagnosed advanced ovarian cancer who achieved a complete response (CR) or partial response (PR) to first-line chemotherapy, according to data from the phase 3 PRIME trial (NCT03709316).1

Among patients who achieved a CR to frontline chemotherapy, those treated with niraparib (n = 212) achieved a median PFS of 29.4 months (95% CI, 19.3–not estimable [NE]) compared with 8.3 months (95% CI, 7.3-12.0) with placebo (n = 103; HR, 0.45; 95% CI, 0.32-0.61; P < .001). In the subgroup of patients who experienced a partial response to chemotherapy, those who were treated with maintenance niraparib (n = 43) had a median PFS of 19.3 months (95% CI, 11.1-NE), vs 8.3 months (95% CI, 5.6-11.1) with placebo (n = 26; HR, 0.45; 95% CI, 0.23-0.86; P = .014).

Notably, those who were treated with niraparib and achieved a CR to first-line chemotherapy experienced a numerically longer PFS than those who experienced a PR (HR, 0.67; 95% CI, 0.43-1.05).

                                                          Ovations for the Cure

                                                         CRUISE FOR A CAUSE

Saturday, September 10, 2022

11am to 2pm


We are so happy to share that after a 2 year wait, we will once again be offering our Cruise for a Cause luncheon cruise aboard the beautiful Spirit of Boston.

 Relax and enjoy a wonderful buffet lunch on the Spirit of Boston.  Then have a blast on the dance floor or venture outside to the outdoor deck space and enjoy the games scattered around the boat! There is no better way to see the beautiful Boston City Skyline than from the Harbor – all while supporting a good cause!

 We have some amazing raffles, 50/50 chances and auctions going on as well!  

 Your ticket to this event will help support our Patient Service Programs which offer much needed support and services to women while they are undergoing treatment for ovarian cancer.